<DOC>
	<DOC>NCT02396966</DOC>
	<brief_summary>The purpose of the protocol is to evaluate and describe QoL, in the population of Polish acromegalic patients treated with Lanreotide Autogel® 120 mg during the 24 months (long term observation).</brief_summary>
	<brief_title>Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>Adult patients with acromegaly treated for at least three months and no longer than three years with Lanreotide Autogel® 120 mg just before inclusion. Patients capable of giving their informed consent to participate in the study and who agree to participate by signing the informed consent form. Active participation in any interventional or any other noninterventional acromegaly clinical study. (Previous participation in any interventional or any observational / post marketing study (PMS) of other somatostatin analogue should not be an exclusion criteria). Any medical or psychological condition, according to investigator judgement, that might compromise the ability to give informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>